The histologic subtype of ovarian tumors affects the detection rate by pelvic washings

Cancer

Volumn 102, Issue 3, 2004, Pages 150-156

  Fadare, Oluwole ^a   Mariappan, M Rajan ^a   Wang, Sa ^a   Hileeto, Denise ^a   Mcalpine, Jessica ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borderline tumors; Ovarian tumors; Pelvic washings; Peritoneal involvement

Indexed keywords

ARTICLE; CLEAR CELL CARCINOMA; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; OVARY TUMOR; PERITONEUM LAVAGE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA, CLEAR CELL; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PELVIS; PERITONEAL CAVITY; PERITONEAL LAVAGE; PERITONEAL NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS;

EID: 2942633630     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20239     Document Type: Article

References (37)

1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97:3133-3275.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
3. Goodman MT, Correa CN, Tung K-H, et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer. 2003;97:2648-2659.
4. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER cancer statistics review, 1973-1997. Bethesda (MD): National Cancer Institute; 2000 NIH Pub No. 00-2789.
5. Keetel WC, Elkins HB. Experience with radioactive colloidal gold in the treatment of ovarian cancer. Am J Obstet Gynecol. 1956;71:553-568.
6. Creasman WT, Rutledge F. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol. 1971;110:773-781.
7. Kottmeier HL, Kolstad P, McGarrity KA, Pettersson F, Ulfelder H. Annual report on the results of treatment in carcinoma of the uterus, vagina, and ovary. Int Fed Gynecol Obstet. Radiumhemmet (Stockholm). 1976;16;1-40.
8. Colgan TJ, Boerner SL, Murphy J, Cole DE, Narod S, Rosen B. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol. 2002;85:397-403.
9. Ravinsky E. Cytology of peritoneal washings in gynecologic patients. Diagnostic criteria and pitfalls. Acta Cytol. 1986;30: 8-16.
10. Mulvany N. Cytohistologic correlation in malignant peritoneal washings. Analysis of 75 malignant fluids. Acta Cytol. 1996;40:1231-1239.
11. Fujiwara K, Yamauchi H, Yoshida T, Suzuki S, Oda T, Kohno I. Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer with unmeasurable disease. Gynecol Oncol. 1998;70:231-235.
12. Yoshimura S, Scully RE, Taft PD, Herrington JB. Peritoneal fluid cytology in patients with ovarian cancer. Gynecol Oncol. 1984;17:161-167.
13. Webb MJ, Snyder JA, Williams TJ, et al. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 1982;14:285-293.
14. Rubin SC, Dulaney ED, Markman M, Hoskins WJ, Saigo PE, Lewis JL. Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma. Obstet Gynecol. 1988;71:851-853.
15. Taft PD, Arizaga-Cruz JM. A comparison of the cell block, Papanicolau, and Millipore filter techniques for the cytologic examination of serous fluids. Am J Clin Pathol. 1960; 34:561-564.
16. Copeland LJ, Gershenson DM, Wharton JT, et al. Microscopic disease at second-look laparotomy in advanced ovarian cancer. Cancer. 1985;55:472-478.
17. Pretorius RG, Lee KR, Papillo J, Baker S, Belinson J. Falsenegative peritoneal cytology in metastatic ovarian carcinoma. Obstet Gynecol. 1986;618:619-623.
18. Ziselman EM, Harkavy SE, Hogan M, West W, Atkinson B. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms. Acta Cytol. 1984;28:105-110.
19. Murphy WM, Ng ABP. Determination of primary site by examination of cancer cells in body fluids. Am J Clin Pathol. 1972;58:479-488.
20. Demay RM. Practical principles of cytopathology. Chicago: ASCP Press, 1999.
21. Takahashi M. Effusions in body cavities. In: Takahashi M, editor. Color atlas of cancer cytology. 3rd edition. Tokyo: Igaku-Shoin, 2000:277-325.
22. Zuna RE, Behrens A. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst. 1996;88:980-987.
23. Prat J, de Nictolis M. Serous borderline tumors of the ovary. A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111-1128.
24. Tavassoli FA. Serous tumor of low-malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol. 1988;1:407-413.
25. Zuna RE, Mitchell ML, Mulick KA, Weijchert WM. Cytohistologic correlation of peritoneal washing cytology in gynecologic disease. Acta Cytol. 1989;33:327-335.
26. Lowe E, McKenna H. Peritoneal washing cytology: a retrospective analysis of 175 gynaecological patients. Aust N Z J Obstet Gynaecol. 1989;29:55-61.
27. Cefis F, Fomi A, Carinelli S, Cangini L. Significance of ascitic fluid and peritoneal washing cytology in ovarian tumor diagnosis. Tumori. 1978;64:77-88.
28. Morton DG, Moore JG, Chang N. The clinical value of peritoneal lavage for cytologic examination. Am J Obstet Gynecol. 1961;81:1115-1125.
29. Keetel WC, Pixley EE, Buchsbaum HJ. Experience with peritoneal cytology in the management of gynecologic malignancies. Am J Obstet Gynecol. 1974;120:174-182.
30. Mathew S, Erozan YS. Significance of peritoneal washings in gynecologic oncology. The experience with 901 intraoperative washings at an academic medical center. Arch Pathol Lab Med. 1997;121:604-606.
31. Johnson TL, Kumar NB, Hopkins M, Hughes JD. Cytologic features of ovarian tumors of low malignant potential in peritoneal fluids. Acta Cytol. 1988;32:513-518.
32. Cheng L, Wolf NG, Rose PG, Rodriguez M, Abdul-Karim FW. Peritoneal washing cytology of ovarian tumors of low malignant potential. Correlation with surface ovarian involvement and peritoneal implants. Acta Cytol. 1998;42:1091-1094.
33. Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a gynecologic oncology group study. J Clin Oncol. 1995;13:2752-2756.
34. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996; 20:1319-1330.
35. Deavers MT, Gershenson DM, Tortolero-Luna G, et al. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential. A study of 99 advanced stage cases. Am J Surg Pathol. 2002;26:1129-1141.
36. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns. A study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999;23:397-409.
37. Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal "implants." Am J Surg Pathol. 1992;16:577-583.